Evan A. Stein
Impact in
- Endocrinology, Diabetes and Metabolism top 0.05%
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Surgery top 0.01%
- Lipoproteins and Cardiovascular Health
Papers in
- Surgery 173
- Lipoproteins and Cardiovascular Health 169
- Cholesterol and Lipid Metabolism 10
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 43
- Co-authors
- Antonio M. Gotto (6 shared papers)Frederick J. Raal (35 shared papers)Deborah R. Shapiro (4 shared papers)Stephen E. Weis (3 shared papers)John R. Downs (3 shared papers)Polly A. Beere (3 shared papers)Edwin J. Whitney (3 shared papers)Alexandra Langendörfer (3 shared papers)
- Journals
- The American Journal of Cardiology (25 papers)Atherosclerosis (24 papers)Journal of the American College of Cardiology (19 papers)Circulation (13 papers)Journal of clinical lipidology (9 papers)
- Partner nations
- United StatesSouth AfricaCanada
In The Last Decade
Evan A. Stein
220 papers receiving 21.7k citations
Evan A. Stein's Hit Papers
Peers
Comparison fields: 5 of 157
- Endocrinology, Diabetes and Metabolism 5.4k
- Surgery 13.8k
- Cancer Research 2.6k
- Cardiology and Cardiovascular Medicine 2.8k
- Economics and Econometrics 2.8k
Countries citing papers authored by Evan A. Stein
This map shows the geographic impact of Evan A. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan A. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan A. Stein more than expected).
Fields of papers citing papers by Evan A. Stein
This network shows the impact of papers produced by Evan A. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan A. Stein. The network helps show where Evan A. Stein may publish in the future.
Co-authors
The 25 scholars most cited alongside Evan A. Stein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 225 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels Hit paper breakdown → | 1998 | 4058 |
| 2 | Estrogen plus Progestin and the Risk of Coronary Heart Disease Hit paper breakdown → | 2003 | 1422 |
| 3 | Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events Hit paper breakdown → | 2015 | 1106 |
| 4 | Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial) Hit paper breakdown → | 2003 | 1096 |
| 5 | Implementation of the women's health initiative study design Hit paper breakdown → | 2003 | 606 |
| 6 | PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2014 | 570 |
| 7 | Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2014 | 561 |
| 8 | Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol Hit paper breakdown → | 2012 | 510 |
| 9 | Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Hit paper breakdown → | 2012 | 463 |
| 10 | THE RELATION OF DIET, CIGARETTE SMOKING, AND ALCOHOL CONSUMPTION TO PLASMA BETA-CAROTENE AND ALPHA-TOCOPHEROL LEVELS Hit paper breakdown → | 1988 | 455 |
| 11 | 2000 | 435 | |
| 12 | Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy Hit paper breakdown → | 2012 | 418 |
| 13 | 1994 | 415 | |
| 14 | Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia Hit paper breakdown → | 2012 | 403 |
| 15 | Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia Hit paper breakdown → | 2012 | 382 |
| 16 | 1995 | 380 | |
| 17 | Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients Hit paper breakdown → | 2012 | 370 |
| 18 | Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) Hit paper breakdown → | 2014 | 282 |
| 19 | 2013 | 266 | |
| 20 | 2012 | 228 |
About Evan A. Stein
Evan A. Stein is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism, Cancer Research, Economics and Econometrics and Cardiology and Cardiovascular Medicine, having authored 225 papers that have together received 22.7k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (169 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (43 papers), Cancer, Lipids, and Metabolism (35 papers), Pharmaceutical Economics and Policy (22 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers), Cholesterol and Lipid Metabolism (10 papers), Lipid metabolism and disorders (10 papers) and Biosimilars and Bioanalytical Methods (7 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (5.4k citations), Surgery (13.8k citations), Cancer Research (2.6k citations), Cardiology and Cardiovascular Medicine (2.8k citations) and Economics and Econometrics (2.8k citations). Evan A. Stein has collaborated with scholars based in United States, South Africa and Canada. Frequent co-authors include Antonio M. Gotto, Frederick J. Raal, Deborah R. Shapiro, Stephen E. Weis, John R. Downs, Polly A. Beere, Edwin J. Whitney, Alexandra Langendörfer, Michael Clearfield and William B. Kruyer. Their work appears in journals such as The American Journal of Cardiology, Atherosclerosis, Journal of the American College of Cardiology, Circulation and Journal of clinical lipidology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.